Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) EBITDA Margin (2023)

Contineum Therapeutics has reported EBITDA Margin over the past 1 years, most recently at 83.02% for Q2 2023.

  • Quarterly results put EBITDA Margin at 83.02% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 38.16% (changed N/A YoY), and the annual figure for FY2023 was 45.81%, changed.
  • EBITDA Margin for Q2 2023 was 83.02% at Contineum Therapeutics, down from 5170.65% in the prior quarter.
  • Over the last five years, EBITDA Margin for CTNM hit a ceiling of 5170.65% in Q1 2023 and a floor of 83.02% in Q2 2023.